Free Trial

HC Wainwright Analysts Increase Earnings Estimates for TRVI

Trevi Therapeutics logo with Medical background

Key Points

  • HC Wainwright has raised its FY2029 earnings estimate for Trevi Therapeutics to $1.79 per share from $1.66, while maintaining a "Buy" rating and a price target of $21.00.
  • Trevi Therapeutics recently reported quarterly earnings of ($0.09) per share, exceeding expectations of ($0.10).
  • Despite the positive outlook from some analysts, the stock has received mixed ratings, with one analyst downgrading it to "sell" while others maintain "buy" or "strong buy" ratings.
  • Want stock alerts on Trevi Therapeutics? Get 5 Weeks of MarketBeat All Access for $5. Get My Stock Alerts.

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Analysts at HC Wainwright lifted their FY2029 earnings estimates for shares of Trevi Therapeutics in a report released on Friday, August 8th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of $1.79 for the year, up from their prior forecast of $1.66. HC Wainwright currently has a "Buy" rating and a $21.00 price objective on the stock. The consensus estimate for Trevi Therapeutics' current full-year earnings is ($0.49) per share.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01.

Several other equities analysts have also weighed in on the stock. Needham & Company LLC reduced their target price on shares of Trevi Therapeutics from $24.00 to $22.00 and set a "buy" rating on the stock in a report on Friday. Raymond James Financial reduced their target price on shares of Trevi Therapeutics from $29.00 to $27.00 and set a "strong-buy" rating on the stock in a report on Friday. Wall Street Zen lowered shares of Trevi Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, June 6th. D. Boral Capital reiterated a "buy" rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a report on Monday, June 2nd. Finally, Cantor Fitzgerald began coverage on shares of Trevi Therapeutics in a report on Tuesday, July 1st. They issued an "overweight" rating and a $25.00 price objective on the stock. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $20.38.

View Our Latest Research Report on TRVI

Trevi Therapeutics Trading Up 1.6%

NASDAQ:TRVI opened at $7.42 on Monday. The firm has a market capitalization of $870.29 million, a price-to-earnings ratio of -17.67 and a beta of 0.58. The firm's fifty day simple moving average is $6.58 and its 200 day simple moving average is $5.94. Trevi Therapeutics has a twelve month low of $2.36 and a twelve month high of $8.11.

Institutional Investors Weigh In On Trevi Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Summit Investment Advisors Inc. increased its position in shares of Trevi Therapeutics by 84.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company's stock worth $26,000 after purchasing an additional 2,894 shares during the last quarter. Strs Ohio bought a new stake in shares of Trevi Therapeutics in the 1st quarter worth about $52,000. Farther Finance Advisors LLC increased its position in shares of Trevi Therapeutics by 15,969.1% in the 2nd quarter. Farther Finance Advisors LLC now owns 8,838 shares of the company's stock worth $48,000 after purchasing an additional 8,783 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Trevi Therapeutics in the 4th quarter worth about $49,000. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of Trevi Therapeutics in the 2nd quarter worth about $75,000. Institutional investors own 95.76% of the company's stock.

About Trevi Therapeutics

(Get Free Report)

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.

Recommended Stories

Earnings History and Estimates for Trevi Therapeutics (NASDAQ:TRVI)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Trevi Therapeutics Right Now?

Before you consider Trevi Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.

While Trevi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Growth Stocks That Could Pop Before Summer Ends
3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines